nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—ABCB1—Lisinopril—dilated cardiomyopathy	0.123	0.532	CbGbCtD
Dapagliflozin—ABCB1—Spironolactone—dilated cardiomyopathy	0.109	0.468	CbGbCtD
Dapagliflozin—UGT2B4—pericardium—dilated cardiomyopathy	0.102	0.307	CbGeAlD
Dapagliflozin—CYP2C9—cardial valve—dilated cardiomyopathy	0.0562	0.169	CbGeAlD
Dapagliflozin—Hypoglycemic reaction—Lisinopril—dilated cardiomyopathy	0.0282	0.0879	CcSEcCtD
Dapagliflozin—SLC5A1—cardiac ventricle—dilated cardiomyopathy	0.0261	0.0785	CbGeAlD
Dapagliflozin—SLC5A1—myocardium—dilated cardiomyopathy	0.0245	0.0738	CbGeAlD
Dapagliflozin—UGT2B4—cardiac ventricle—dilated cardiomyopathy	0.024	0.0723	CbGeAlD
Dapagliflozin—UGT2B4—myocardium—dilated cardiomyopathy	0.0226	0.068	CbGeAlD
Dapagliflozin—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.0221	0.0691	CcSEcCtD
Dapagliflozin—Diuresis—Furosemide—dilated cardiomyopathy	0.0221	0.0691	CcSEcCtD
Dapagliflozin—SLC5A1—heart—dilated cardiomyopathy	0.0171	0.0515	CbGeAlD
Dapagliflozin—UGT2B4—heart—dilated cardiomyopathy	0.0158	0.0475	CbGeAlD
Dapagliflozin—SLC5A1—cardiac atrium—dilated cardiomyopathy	0.0146	0.0441	CbGeAlD
Dapagliflozin—UGT2B4—cardiac atrium—dilated cardiomyopathy	0.0135	0.0406	CbGeAlD
Dapagliflozin—SLC5A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00964	0.0838	CbGpPWpGaD
Dapagliflozin—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00837	0.0261	CcSEcCtD
Dapagliflozin—Fluid overload—Lisinopril—dilated cardiomyopathy	0.00828	0.0258	CcSEcCtD
Dapagliflozin—SLC5A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00703	0.0612	CbGpPWpGaD
Dapagliflozin—Renal failure—Spironolactone—dilated cardiomyopathy	0.00694	0.0216	CcSEcCtD
Dapagliflozin—Urine output increased—Furosemide—dilated cardiomyopathy	0.00621	0.0194	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00573	0.0179	CcSEcCtD
Dapagliflozin—Polyuria—Furosemide—dilated cardiomyopathy	0.00567	0.0177	CcSEcCtD
Dapagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00533	0.0463	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00533	0.0463	CbGpPWpGaD
Dapagliflozin—Thirst—Furosemide—dilated cardiomyopathy	0.00523	0.0163	CcSEcCtD
Dapagliflozin—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.005	0.0156	CcSEcCtD
Dapagliflozin—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00491	0.0148	CbGeAlD
Dapagliflozin—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00486	0.0152	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00467	0.0146	CcSEcCtD
Dapagliflozin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00464	0.0145	CcSEcCtD
Dapagliflozin—Dehydration—Furosemide—dilated cardiomyopathy	0.00463	0.0145	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00455	0.0142	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.0045	0.014	CcSEcCtD
Dapagliflozin—SLC5A11—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00438	0.0381	CbGpPWpGaD
Dapagliflozin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.0043	0.0134	CcSEcCtD
Dapagliflozin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00398	0.0124	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00389	0.0121	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00383	0.0119	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00381	0.0119	CcSEcCtD
Dapagliflozin—Renal failure—Furosemide—dilated cardiomyopathy	0.00377	0.0118	CcSEcCtD
Dapagliflozin—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00375	0.0117	CcSEcCtD
Dapagliflozin—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00374	0.0117	CcSEcCtD
Dapagliflozin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00358	0.0112	CcSEcCtD
Dapagliflozin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00356	0.0111	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.0035	0.0109	CcSEcCtD
Dapagliflozin—Dehydration—Lisinopril—dilated cardiomyopathy	0.00348	0.0108	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00341	0.0106	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.0034	0.0106	CcSEcCtD
Dapagliflozin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00338	0.0105	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00334	0.0104	CcSEcCtD
Dapagliflozin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00332	0.0103	CcSEcCtD
Dapagliflozin—Influenza—Lisinopril—dilated cardiomyopathy	0.00323	0.0101	CcSEcCtD
Dapagliflozin—CYP1A1—heart—dilated cardiomyopathy	0.00323	0.00971	CbGeAlD
Dapagliflozin—SLC5A4—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.0032	0.0278	CbGpPWpGaD
Dapagliflozin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00315	0.00982	CcSEcCtD
Dapagliflozin—CYP2C9—heart—dilated cardiomyopathy	0.00311	0.00935	CbGeAlD
Dapagliflozin—Dysuria—Lisinopril—dilated cardiomyopathy	0.00302	0.00942	CcSEcCtD
Dapagliflozin—Malnutrition—Furosemide—dilated cardiomyopathy	0.003	0.00936	CcSEcCtD
Dapagliflozin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00298	0.00928	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00284	0.00886	CcSEcCtD
Dapagliflozin—Rash—Spironolactone—dilated cardiomyopathy	0.00284	0.00885	CcSEcCtD
Dapagliflozin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00284	0.00884	CcSEcCtD
Dapagliflozin—Renal failure—Lisinopril—dilated cardiomyopathy	0.00283	0.00883	CcSEcCtD
Dapagliflozin—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00282	0.00881	CcSEcCtD
Dapagliflozin—Headache—Spironolactone—dilated cardiomyopathy	0.00282	0.00879	CcSEcCtD
Dapagliflozin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.0028	0.00873	CcSEcCtD
Dapagliflozin—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.00276	0.00831	CbGeAlD
Dapagliflozin—Nausea—Spironolactone—dilated cardiomyopathy	0.00267	0.00834	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00255	0.00797	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00254	0.00791	CcSEcCtD
Dapagliflozin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00253	0.00791	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00245	0.00764	CcSEcCtD
Dapagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00242	0.0211	CbGpPWpGaD
Dapagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00242	0.0211	CbGpPWpGaD
Dapagliflozin—Skin disorder—Furosemide—dilated cardiomyopathy	0.00238	0.00742	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00237	0.00738	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00229	0.0199	CbGpPWpGaD
Dapagliflozin—Hypotension—Furosemide—dilated cardiomyopathy	0.00229	0.00714	CcSEcCtD
Dapagliflozin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00225	0.00702	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00223	0.0194	CbGpPWpGaD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00223	0.0194	CbGpPWpGaD
Dapagliflozin—Back pain—Lisinopril—dilated cardiomyopathy	0.00218	0.00679	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00211	0.00659	CcSEcCtD
Dapagliflozin—Constipation—Furosemide—dilated cardiomyopathy	0.00209	0.00653	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00207	0.018	CbGpPWpGaD
Dapagliflozin—Angioedema—Lisinopril—dilated cardiomyopathy	0.00206	0.00642	CcSEcCtD
Dapagliflozin—UGT1A9—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00199	0.0173	CbGpPWpGaD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00195	0.0169	CbGpPWpGaD
Dapagliflozin—Urticaria—Furosemide—dilated cardiomyopathy	0.00195	0.00607	CcSEcCtD
Dapagliflozin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00194	0.00604	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.0019	0.00594	CcSEcCtD
Dapagliflozin—Discomfort—Lisinopril—dilated cardiomyopathy	0.00189	0.00591	CcSEcCtD
Dapagliflozin—Oedema—Lisinopril—dilated cardiomyopathy	0.00184	0.00573	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00184	0.00573	CcSEcCtD
Dapagliflozin—Infection—Lisinopril—dilated cardiomyopathy	0.00183	0.00569	CcSEcCtD
Dapagliflozin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0018	0.00563	CcSEcCtD
Dapagliflozin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00178	0.00557	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00178	0.00554	CcSEcCtD
Dapagliflozin—Hypotension—Lisinopril—dilated cardiomyopathy	0.00172	0.00536	CcSEcCtD
Dapagliflozin—ABCB1—heart—dilated cardiomyopathy	0.00168	0.00504	CbGeAlD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00167	0.0145	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00162	0.0141	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00162	0.0141	CbGpPWpGaD
Dapagliflozin—Dizziness—Furosemide—dilated cardiomyopathy	0.00162	0.00505	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00159	0.00495	CcSEcCtD
Dapagliflozin—Constipation—Lisinopril—dilated cardiomyopathy	0.00157	0.0049	CcSEcCtD
Dapagliflozin—Rash—Furosemide—dilated cardiomyopathy	0.00154	0.00482	CcSEcCtD
Dapagliflozin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00154	0.00481	CcSEcCtD
Dapagliflozin—Headache—Furosemide—dilated cardiomyopathy	0.00153	0.00478	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00151	0.0131	CbGpPWpGaD
Dapagliflozin—Urticaria—Lisinopril—dilated cardiomyopathy	0.00146	0.00455	CcSEcCtD
Dapagliflozin—Nausea—Furosemide—dilated cardiomyopathy	0.00145	0.00454	CcSEcCtD
Dapagliflozin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00145	0.00453	CcSEcCtD
Dapagliflozin—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00144	0.0125	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00135	0.00422	CcSEcCtD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00134	0.0117	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00127	0.011	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00127	0.011	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00123	0.0107	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00123	0.0107	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00123	0.0107	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00123	0.0107	CbGpPWpGaD
Dapagliflozin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00121	0.00379	CcSEcCtD
Dapagliflozin—Rash—Lisinopril—dilated cardiomyopathy	0.00116	0.00361	CcSEcCtD
Dapagliflozin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00116	0.00361	CcSEcCtD
Dapagliflozin—Headache—Lisinopril—dilated cardiomyopathy	0.00115	0.00359	CcSEcCtD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00114	0.00995	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00114	0.00995	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00114	0.00992	CbGpPWpGaD
Dapagliflozin—CYP1A1—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00112	0.00972	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00112	0.00971	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.0011	0.00954	CbGpPWpGaD
Dapagliflozin—Nausea—Lisinopril—dilated cardiomyopathy	0.00109	0.0034	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—TAZ—dilated cardiomyopathy	0.00103	0.00897	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—SDHA—dilated cardiomyopathy	0.000933	0.00811	CbGpPWpGaD
Dapagliflozin—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000841	0.00731	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000832	0.00723	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000832	0.00723	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—TAZ—dilated cardiomyopathy	0.000782	0.0068	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—TAZ—dilated cardiomyopathy	0.000782	0.0068	CbGpPWpGaD
Dapagliflozin—CYP1A1—Oxidative Stress—SOD2—dilated cardiomyopathy	0.000782	0.00679	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00077	0.00669	CbGpPWpGaD
Dapagliflozin—CYP1A1—Oxidative Stress—GPX1—dilated cardiomyopathy	0.000746	0.00648	CbGpPWpGaD
Dapagliflozin—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000713	0.0062	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—SDHA—dilated cardiomyopathy	0.000707	0.00615	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—SDHA—dilated cardiomyopathy	0.000707	0.00615	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000642	0.00558	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—TAZ—dilated cardiomyopathy	0.000604	0.00525	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NPPA—dilated cardiomyopathy	0.000571	0.00496	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PSEN2—dilated cardiomyopathy	0.000553	0.0048	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—SDHA—dilated cardiomyopathy	0.000546	0.00475	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000534	0.00464	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000516	0.00448	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000502	0.00436	CbGpPWpGaD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000495	0.00431	CbGpPWpGaD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000452	0.00393	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000447	0.00389	CbGpPWpGaD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000438	0.0038	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NPPA—dilated cardiomyopathy	0.000432	0.00376	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NPPA—dilated cardiomyopathy	0.000432	0.00376	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PSEN2—dilated cardiomyopathy	0.000419	0.00364	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PSEN2—dilated cardiomyopathy	0.000419	0.00364	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000406	0.00353	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000403	0.0035	CbGpPWpGaD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000394	0.00342	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000385	0.00335	CbGpPWpGaD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00037	0.00321	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000366	0.00319	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000342	0.00297	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000329	0.00286	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000329	0.00286	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000322	0.0028	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000316	0.00275	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000307	0.00266	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000302	0.00262	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000293	0.00254	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000288	0.00251	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000287	0.00249	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—RAC1—dilated cardiomyopathy	0.000278	0.00242	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TAZ—dilated cardiomyopathy	0.000275	0.00239	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000271	0.00236	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000266	0.00232	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000257	0.00223	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000257	0.00223	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—GPX1—dilated cardiomyopathy	0.000254	0.0022	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000251	0.00218	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.00025	0.00217	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.00025	0.00217	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SDHA—dilated cardiomyopathy	0.000249	0.00216	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—CD36—dilated cardiomyopathy	0.000247	0.00215	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000238	0.00207	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000231	0.00201	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000229	0.00199	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000226	0.00197	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TAZ—dilated cardiomyopathy	0.000223	0.00194	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AGT—dilated cardiomyopathy	0.000222	0.00193	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000221	0.00192	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000221	0.00192	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000215	0.00187	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—RAC1—dilated cardiomyopathy	0.000211	0.00183	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—RAC1—dilated cardiomyopathy	0.000211	0.00183	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.00021	0.00183	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00021	0.00183	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000206	0.00179	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SDHA—dilated cardiomyopathy	0.000202	0.00176	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000195	0.0017	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GPX1—dilated cardiomyopathy	0.000192	0.00167	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GPX1—dilated cardiomyopathy	0.000192	0.00167	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CD36—dilated cardiomyopathy	0.000187	0.00163	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—CD36—dilated cardiomyopathy	0.000187	0.00163	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—RAF1—dilated cardiomyopathy	0.000184	0.0016	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000184	0.0016	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000183	0.00159	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000173	0.00151	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	0.000172	0.0015	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AGT—dilated cardiomyopathy	0.000168	0.00146	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AGT—dilated cardiomyopathy	0.000168	0.00146	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000166	0.00144	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000161	0.0014	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000161	0.0014	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000156	0.00136	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	0.000156	0.00135	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00015	0.0013	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GPX1—dilated cardiomyopathy	0.000148	0.00129	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CD36—dilated cardiomyopathy	0.000144	0.00126	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000141	0.00123	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000141	0.00123	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—RAF1—dilated cardiomyopathy	0.00014	0.00121	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—RAF1—dilated cardiomyopathy	0.00014	0.00121	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000137	0.00119	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000134	0.00117	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000134	0.00117	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000131	0.00114	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AGT—dilated cardiomyopathy	0.00013	0.00113	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	0.000128	0.00112	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000127	0.0011	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EGFR—dilated cardiomyopathy	0.000126	0.0011	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000124	0.00108	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000123	0.00107	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00012	0.00104	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	0.000116	0.00101	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000109	0.000948	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000109	0.000948	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000108	0.00094	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000103	0.000893	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000103	0.000891	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000102	0.000886	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	9.66e-05	0.00084	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	9.58e-05	0.000833	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—dilated cardiomyopathy	9.57e-05	0.000832	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—dilated cardiomyopathy	9.57e-05	0.000832	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	9.27e-05	0.000806	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	8.74e-05	0.00076	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	8.71e-05	0.000757	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	8.66e-05	0.000753	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	8.24e-05	0.000716	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	8.18e-05	0.000711	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	7.4e-05	0.000643	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.08e-05	0.000616	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.9e-05	0.000599	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GPX1—dilated cardiomyopathy	6.76e-05	0.000587	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	6.72e-05	0.000584	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CD36—dilated cardiomyopathy	6.58e-05	0.000572	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	6.32e-05	0.000549	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.21e-05	0.00054	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AGT—dilated cardiomyopathy	5.92e-05	0.000515	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	5.71e-05	0.000497	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.65e-05	0.000491	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	5.49e-05	0.000477	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	5.38e-05	0.000468	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	5.35e-05	0.000465	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.28e-05	0.000459	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.15e-05	0.000447	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	4.81e-05	0.000419	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.63e-05	0.000403	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.52e-05	0.000392	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.4e-05	0.000382	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	4.23e-05	0.000368	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	4.12e-05	0.000358	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.96e-05	0.000344	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	3.71e-05	0.000323	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.27e-05	0.000284	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	3.15e-05	0.000274	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	3.07e-05	0.000267	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	2.77e-05	0.00024	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.52e-05	0.000219	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.45e-05	0.000213	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	2.37e-05	0.000206	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	2.35e-05	0.000205	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	2.31e-05	0.000201	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	2.29e-05	0.000199	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.21e-05	0.000192	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.08e-05	0.000181	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	2.06e-05	0.000179	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	2.01e-05	0.000175	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.96e-05	0.00017	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.76e-05	0.000153	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.55e-05	0.000135	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.51e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.36e-05	0.000118	CbGpPWpGaD
